Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Efficacy and Safety of Mycophenolate Mofetil in Patients With Active Moderate-to-Severe Graves’ Orbitopathy
source: Clinical Endocrinology (Oxford)
year: 2017
authors: Ye X, Bo X, Hu X, Cui H, Lu B, Shao J, Wang J
summary/abstract:Context:
Graves’ orbitopathy (GO) is a potentially sight-threatening disease for which currently available medical therapy is not reliably successful. Mycophenolate mofetil (MMF) is a selective immunosuppressant used widely in many autoimmune diseases. Preliminary studies have shown that MMF is effective in the treatment of active GO.
Objective:
To evaluate the efficacy and safety of MMF in patients with active moderate-to-severe GO.
Patients:
One hundred and 74 patients with active moderate-to-severe GO were randomized to receive either MMF or glucocorticoids (GC).
Main Outcome Measures:
The primary outcome was overall response at the 12th and 24th weeks; the outcome assessments included clinical activity score (CAS), soft tissue involvement, pain, visual acuity, proptosis, diplopia and reduction in eye movements. The secondary outcome was changes in those individual parameters. Adverse effects were recorded at each visit.
Results:
A greater overall response rate was found in the MMF group compared with the GC group at the 24th week (91•3% vs 67•9%, P = 0•000). MMF therapy showed a better CAS response than GC (92•5% vs 70•5% improved, P < 0•05). Patients treated with MMF showed a significantly improved rate of diplopia and proptosis than patients treated with GC at the 24th week (90•4% and 68•8% improved, respectively). Disease reactivation was not observed in the patients treated with MMF but was observed in five patients after GC therapy. Adverse events occurred in 4 of 80 patients treated with MMF (5%), all of which were mild to moderate. A severe adverse event was only observed in one patient treated with GC but not at all in patients treated with MMF.
Conclusion:
Compared with GC treatment, MMF therapy is more effective and safer for patients with active moderate-to-severe GO.
DOI: 10.1111/cen.13170
read more
myBinderRelated Content
-
Update on Graves’ Disease: Advances in Treatment of Mild, Moderate and Severe Thyroid Eye DiseasePurpose of Review: To report the most r...
-
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Lif...Horizon Therapeutics plc today announced...
-
Sensitivity and Responsiveness of the Patient-Reported TED-QOL to Rehabilitative Surgery in Thyroid Eye DiseaseWe tested the sensitivity and responsive...
-
Common Immunosuppressive Monotherapy for Graves’ Ophthalmopathy: A Meta-AnalysisBackground: Several immunosuppressive t...
-
Prospective, Systematically Recorded Mycophenolate Safety Data in Graves’ OrbitopathyContext: The antiproliferative mechanis...
-
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Gr...Background: High-dose intravenous gluco...
-
Teprotumumab, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody, in the Treatment of Active Thyroid eye D...Thyroid eye disease is a disabling autoi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google